NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

Rhea-AI Summary

NurExone (OTCQB: NRXBF) announced it received C$3,185,994.43 in gross proceeds from accelerated warrant exercises completed after acceleration notices issued on October 8, 2025.

The company reported C$1,207,418.88 from 2,515,456 September 2023 warrants at C$0.48 each and C$1,978,575.55 from 5,653,073 January 2024 warrants at C$0.35 each. Proceeds will be used for general corporate purposes and working capital to support development of its exosome-based therapeutic platform, including ExoPTEN. NurExone also received finalist recognition at Falling Walls (Berlin) and Prix Galien Bridges (Stockholm, December 5, 2025).

Positive

• Gross proceeds of C$3,185,994.43
• Exercise of 8,168,529 warrants completed
• Proceeds allocated to working capital and clinical development
• Full warrantholder participation signaling investor confidence

Negative

• Issuance of 8,168,529 shares from exercised warrants may dilute existing shareholders

NurExone Honored at Berlin and Stockholm Conferences for Breakthrough Contributions to Global Life Sciences and Health Innovation

TORONTO and HAIFA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that, further to its press release dated October 8, 2025 (the “October 8 Release”), the Company has received gross proceeds of over C$3.18M through accelerated warrant exercises.

The breakdown of the proceeds is as follows: (i) C$1,207,418.88 through the exercise of 2,515,456 September 2023 Warrants at a price of C$0.48 per September 2023 Warrant issued from a non-brokered private placement which closed in tranches on August 25, 2023 and September 6, 2023 and (ii) C$1,978,575.55 through the exercise of 5,653,073 January 2024 Warrants at a price of C$0.35 per January 2024 Warrant issued from a non-brokered private placement which closed on January 4, 2024. Capitalized terms not otherwise defined herein have the meanings attributed to them in the October 8 Release.

Following the Company providing the outstanding holders of the September 2023 Warrants and January 2024 Warrants acceleration notices on October 8, 2025 notifying them that their acceleration triggers were met, when the daily volume average trading price of the Common Shares on the TSXV equaled or exceeded C$0.83, in the case of the September 2023 Warrants, and C$0.80, in the case of the January 2024 Warrants, for a period of 20 consecutive trading days, all of the September 2023 Warrants and January 2024 Warrants were exercised their warrants prior to expiry, providing the Company an aggregate of C$3,185,994.43 in gross proceeds.

The proceeds from these exercises strengthen NurExone’s balance sheet and will be used for general corporate purposes and working capital, supporting ongoing development of Company’s exosome-based therapeutic platform.

Management Commentary

“We are very pleased with the full participation from warrantholders during the accelerated exercise period,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “This additional capital enhances our financial strengths as we continue advancing ExoPTEN and our therapeutic pipeline towards clinical readiness.”

Eran Ovadya, Chief Financial Officer of NurExone, added: “The full participation of these warrantholders reflects investor confidence in NurExone’s strategy and our exosome-based platform. The resulting funds provide further financial stability, enabling us to efficiently allocate resources towards clinical development and key operational priorities, while maintaining a strong balance sheet.”

Global Recognition of Translational Innovation

Alongside these financial milestones, NurExone’s scientific progress continues to gain international recognition. The Company has been nominated as a finalist for the Galien Foundation’s inaugural Prix Galien Bridges Awards. The award event, which will be held at the Nobel Forum in Stockholm on December 5, 2025, celebrates life sciences innovation that transcends geographic and disciplinary boundaries. Earlier this month, NurExone was also recognized as a finalist in the Falling Walls Science Breakthroughs of the Year Summit in Berlin.

“Our recognition among leading innovators in Europe, from Prix Galien in Stockholm to Falling Walls in Berlin, highlights our growing leadership position in exosome-based medicine,” noted Dr. Tali Kizhner, Director of Research and Development at NurExone. “We are proud to represent a new wave of regenerative biotechnology with the potential to connect scientific excellence with tangible human impact.”

About the Galien Foundation

The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation that improves the human condition. Established in honor of Galen, the father of modern medicine, the Galien Foundation oversees the international Prix Galien Bridges Awards, regarded as the industry’s highest accolade for biopharmaceutical research and innovation. The Prix Galien Bridges Awards extend this legacy by connecting innovators across regions and disciplines to advance the next generation of global health breakthroughs.

About NurExone

NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed biotechnology company developing regenerative exosome-based therapies for central nervous system injuries. Its lead candidate, ExoPTEN, has shown compelling preclinical data supporting clinical potential in acute spinal cord and optic nerve injury, both multi-billion-dollar marketsⁱ. Key regulatory milestones, including Orphan Drug Designation from the FDA and EMA, are paving the way towards clinical trials in the U.S. and Europe. NurExone has established Exo-Top Inc., a U.S. subsidiary, to produce and supply GMP-compliant exosomes for self-use, regenerative aesthetics and other indications as part of its commercial growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com

FORWARD-LOOKING STATEMENTS

This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the use of proceeds and benefits from the warrant exercises; the benefits of being selected as a finalist and the opportunities that it may yield; the Company continuing to advance ExoPTEN and their therapeutic pipeline towards clinical readiness; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: ExoPTEN will yield the benefits outlined herein; being selected as a finalist will yield the benefits and opportunities outlined herein; the use of proceeds from the warrant exercises will be utilized as set out herein; the warrant exercises will have the benefits on the Company as set out herein; the Company will continue to advance ExoPTEN and their therapeutic pipeline towards clinical readiness; and the NurExone platform technology has the ability to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company’s early stage of development; lack of revenues to date; the inherent uncertainty of preclinical drug development, including the risk that product candidates may not advance to clinical trials or receive regulatory approval; the possibility that results from preclinical studies and early-stage trials may not predict later outcomes; the uncertain timing, cost, and outcome of preclinical and clinical development activities; risks related to the clinical trial process, including potential delays or failure to achieve effective trial design or positive results; the inability to obtain or maintain required regulatory approvals; limited market acceptance of the Company’s products, even if approved; the potential emergence of competing therapies that are safer, more effective, or more affordable; rapid technological change that may impact the relevance of the Company’s technologies; the Company’s dependence on key personnel and strategic partners; the inability to obtain adequate financing; risks related to the Company’s ability to protect its intellectual property; the possibility that the Company’s technologies, including its exosome-based platforms, may not achieve their intended therapeutic impact; the inability to produce or scale exosome-based products for clinical use; limited adoption in regenerative medicine or cell therapy applications; lack of growing clinical demand in targeted indications such as spinal cord injury, optic nerve repair, or other therapeutic areas; failure to meet planned development milestones or achieve commercial breakthroughs; ExoPTEN will not yield the benefits outlined herein; being selected as a finalist will not yield the benefits and/or opportunities outlined herein; the use of proceeds from the warrant exercises will not be utilized as set out herein; the warrant exercises will not have the benefits on the Company as set out herein; the Company will be unable to continue to advance ExoPTEN and/or their therapeutic pipeline towards clinical readiness; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s annual information form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

____________________
ⁱ Spinal cord injury, Glaucoma

FAQ

How much did NurExone (NRXBF) raise through accelerated warrant exercises on November 12, 2025?

NurExone raised C$3,185,994.43 in gross proceeds from accelerated warrant exercises.

How many warrants did NurExone (NRXBF) have exercised and at what prices?

A total of 8,168,529 warrants were exercised: 2,515,456 at C$0.48 and 5,653,073 at C$0.35.

What will NurExone (NRXBF) use the proceeds for?

Proceeds will be used for general corporate purposes and working capital, supporting clinical development of ExoPTEN.

Does the warrant exercise create dilution for NurExone (NRXBF) shareholders?

Yes. The exercise resulted in issuance of 8,168,529 shares, which may dilute existing shareholders.

When and where is NurExone scheduled for the Prix Galien Bridges Awards event?

The Prix Galien Bridges Awards event is scheduled at the Nobel Forum in Stockholm on December 5, 2025.